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ripheral sympathetic nervous system. High-risk NB is charac-
terized byMYCN amplification and human telomerase reverse
transcriptase (hTERT) rearrangement, contributing to hTERT
activation and a poor outcome. For targeting hTERT-activated
tumors, we developed two oncolytic adenoviruses, OBP-301
and tumor suppressor p53-armed OBP-702, in which the
hTERT promoter drives expression of the viral E1 gene for tu-
mor-specific virus replication. In this study, we demonstrate
the therapeutic potential of the hTERT-driven oncolytic adeno-
viruses OBP-301 and OBP-702 using four human MYCN-
amplified NB cell lines (IMR-32, CHP-134, NB-1, LA-N-5)
exhibiting high hTERT expression. OBP-301 and OBP-702 ex-
hibited a strong antitumor effect in association with autophagy
in NB cells. Virus-mediated activation of E2F1 protein sup-
pressed MYCN expression. OBP-301 and OBP-702 signifi-
cantly suppressed the growth of subcutaneous CHP-134 tu-
mors. Thus, these hTERT-driven oncolytic adenoviruses are
promising antitumor agents for eliminating MYCN-amplified
NB cells via E2F1-mediated suppression of MYCN protein.Received 1 May 2020; accepted 27 May 2020;
https://doi.org/10.1016/j.omto.2020.05.015.
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Neuroblastoma (NB) is amalignancy of the peripheral sympathetic ner-
vous system.1 NB is the most common extracranial solid tumor, ac-
counting for 15% of all childhood cancer deaths.2 The biological
behavior of NB differs considerably between low-risk and high-risk
NB tumors. Low-risk NB tumors spontaneously disappear or differen-
tiate into benign tumors, whereas high-riskNB tumors rapidly progress
and exhibit an invasive andmetastatic phenotype.3 Amplification of the
MYCN oncogene is one of the most critical prognostic factors in high-
riskNB tumors.4 BecauseMYCN is strongly associatedwith progressive
disease and unfavorable prognosis in high-risk NB,4 MYCN is thought
to play a central role inmaintaining themalignant potential of high-risk
NB tumors, suggesting thatMYCN is an attractive therapeutic target for
the treatment of this disease.5However, it has been extremely difficult to
develop a specific inhibitor that directly targets MYCNprotein in high-14 Molecular Therapy: Oncolytics Vol. 18 September 2020 ª 2020 The
This is an open access article under the CC BY license (http://creativrisk NB.6 In contrast, the results of recent comprehensive genomic an-
alyses suggested that human telomerase reverse transcriptase (hTERT)
rearrangement is a novel prognostic factor in high-risk NB tumors.7,8
Interestingly, high-risk NB tumors exhibiting MYCN amplification
and hTERT rearrangement have similar characteristics with transcrip-
tional activation of hTERT expression. Therefore, high hTERT expres-
sionmay be a novel therapeutic target for the treatment of high-riskNB
involving MYCN amplification and/or hTERT rearrangement.
Oncolytic virotherapy has recently emerged as a novel antitumor mo-
dality for inducing specific deathof tumor cellswithout affectingnormal
cells.9 To target hTERT-activated malignant tumor cells, we developed
two types of hTERT-driven oncolytic adenoviruses, OBP-301 (Telome-
lysin)10 and tumor suppressor p53-expressing OBP-702,11 in which
the hTERT promoter drives the E1 gene for tumor-specific virus
replication. OBP-301 and OBP-702 demonstrated therapeutic
potential for inducing lytic death in association with autophagy and
apoptosis in a variety of human cancer cells expressing hTERT.11–14
A phase I clinical trial conducted in patients with advanced solid
tumors in the United States showed that OBP-301 was well tolerated
by patients.15 In addition, a preclinical study demonstrated that
OBP-301 sensitizes tumor cells to radiotherapy,16 and a phase I/II study
of OBP-301 in combination with radiotherapy is currently ongoing in
patients with esophageal cancer. Because high-risk NB tumors exhibit
high hTERT expression, hTERT-targeted oncolytic virotherapy may
be an ideal antitumor strategy for the treatment of this disease.
In the present study, we investigated the therapeutic potential of the
hTERT-driven oncolytic adenoviruses OBP-301 and OBP-702 against
MYCN-amplified NB cells. To elucidate the molecular mechanismAuthor(s).
ecommons.org/licenses/by/4.0/).
Figure 1. Expression of CAR Protein and Human
Telomerase Reverse Transcriptase (hTERT) mRNA
in Human NB Cells Exhibiting MYCN Amplification
(A) Expression of CAR protein in human NB cells was
analyzed using flow cytometry. Cells were incubated with
mouse anti-CAR monoclonal antibody, followed by detec-
tion with an FITC-labeled secondary antibody. Isotype-
matched normal mouse IgG was used as a control. (B)
ExpressionofhTERTmRNAwasanalyzedusingqRT-PCR.
The expression level of hTERT mRNA was calculated rela-
tive to that of hTERTmRNA inH1299cells,whichwas set at
1. Data are expressed asmean± SD (n = 3). (C) Expression
of MYCN protein in human NB cells was analyzed using
western blotting. b-Actin was assayed as a loading control.
www.moleculartherapy.orgunderlying the virus-induced antitumor effect, we assessed themodula-
tion of apoptosis- and autophagy-related markers andMYCN in virus-
infected NB cells. Finally, the in vivo antitumor effect of the oncolytic
adenoviruses was evaluated using a subcutaneous NB xenograft tumor
model.
RESULTS
Expression of CAR and hTERT in MYCN-Amplified NB Cells
Adenovirus serotype 5 (Ad5) enters target cells via binding of the viral
fiber knob to the coxsackievirus and adenovirus receptor (CAR) pro-
tein.17 To evaluate the therapeutic potential of the hTERT-driven on-
colytic adenoviruses, which are generated based on the Ad5 genome,
in NB cells, we measured the expression level of cell surface CAR pro-
tein in four human MYCN-amplified NB cell lines (IMR-32, CHP-
134, NB-1, LA-N-5) using flow cytometry analysis. All of the NB
cell lines exhibited CAR expression on the cell surface (Figure 1A).
Next, we measured the expression level of hTERT mRNA in
MYCN-amplified NB cells using real-time RT-PCR analysis.
Compared to human lung cancer H1299 cells, all of the NB cell lines
exhibited approximately 2- to 13-fold higher expression of hTERT
mRNA (Figure 1B). In contrast, no hTERTmRNA expression was de-
tected in normal human lung fibroblastWI38 cells (Figure 1B). More-
over, we confirmed the expression of MYCN protein in the MYCN-
amplified NB cell lines by western blot (Figure 1C). The observed
expression of CAR and hTERT suggests that MYCN-amplified NB
cells are sensitive to hTERT-driven oncolytic adenoviruses.
In Vitro Cytopathic Effect of hTERT-Driven Oncolytic
Adenoviruses against MYCN-Amplified NB Cells
To investigate the therapeutic potential of the hTERT-driven
oncolytic adenoviruses against MYCN-amplified NB cells, the
viability of NB cells was evaluated on day 3 after virus infection using
an sodium 3’-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis (4-me-Molecular Ththoxy-6-nitro) benzene sulfonic acid hydrate
(2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)2H-
tetrazolium-5-carboxanilide) assay. Both OBP-
301 and OBP-702 significantly decreased the
viability of all NB cells in a dose-dependent
manner (Figure 2A; Figure S1). The viabilityof IMR-32 and LA-N-5 cells was further decreased on day 5 after virus
infection (Figure S2). Compared to OBP-301, OBP-702 exhibited a
stronger antitumor effect against all NB cell lines examined. As SK-
N-SH cells have been reported as non-MYCN-amplified NB cells
with high hTERT expression,18 we analyzed the expression of hTERT
mRNA and virus sensitivity in SK-N-SH cells. Non-MYCN-amplified
SK-N-SH cells showed high hTERT expression and were sensitive to
OBP-301 and OBP-702 as similar with MYCN-amplified NB cells
(Figures S3 and S4A). These results suggest that hTERT-expressing
NB cells are sensitive to OBP-301 and OBP-702.
To explore the underlying mechanism of the virus-mediated anti-
tumor effect against MYCN-amplified NB cells, we investigated the
expression of apoptosis- and autophagy-related proteins on day 3 after
virus infection using western blot analysis. No increase in expression
of the apoptosis-relatedmarker cleaved poly(ADP-ribose) polymerase
(PARP) protein was observed after infection with OBP-301 or OBP-
702 (Figure 2B). In contrast, both OBP-301 and OBP-702 induced
an increase in expression of the autophagy-relatedmarker LC3-II pro-
tein, which is converted from LC3-I protein during autophagy induc-
tion.However, the expression of p62was not detected inNB cells (data
not shown). Expression of adenoviral E1A protein was increased in all
NB cells infected with either OBP-301 or OBP-702, whereas p53
expression was decreased by OBP-301 and increased by OBP-702.
In contrast, non-MYCN-amplified NB cells showed apoptosis and
autophagy after virus infection (Figure S4B). These results suggest
that the antitumor effect of both OBP-301 and OBP-702 is associated
with the induction of autophagy in MYCN-amplified NB cells.
hTERT-Driven Oncolytic Adenoviruses Downregulate MYCN
Expression
MYCN plays a crucial role in maintaining the malignant po-
tential of MYCN-amplified NB cells. Therefore, we evaluatederapy: Oncolytics Vol. 18 September 2020 15
Figure 2. In Vitro Cytopathic Effect of OBP-301 and OBP-702 in Association with Autophagy in Human NB Cells
(A) IMR-32 and CHP-134 cells were infected with OBP-301 or OBP-702 at the indicated MOI, and cell viability was evaluated using an XTT assay on day 3 after infection. Cell
viability was calculated relative to that of mock-infected cells, which was set at 1.0. Cell viability data are expressed as mean ± SD (n = 5). *p < 0.05 (versus an MOI of 0). (B)
Expression of viral E1A, p53, PARP, cleaved PARP (C-PARP), and microtubule-associated protein 1 light chain 3 (LC3) protein in IMR-32 and CHP-134 cells infected with
OBP-301 or OBP-702 at the indicated MOI for 72 h. b-Actin was assayed as a loading control.
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amplified NB cells infected with OBP-301 or OBP-702. The
expression of both MYCN mRNA and protein was downregu-
lated in a dose-dependent manner in OBP-301- and OBP-702-
infected NB cells (Figures 3A and 3B). To explore the under-
lying mechanism of virus-induced MYCN downregulation, we
examined the role of E2F1, which is the downstream mediator
of viral E1A protein. E2F1 expression was upregulated in a
dose-dependent manner in OBP-301- and OBP-702-infected
NB cells (Figure 3B). A significant reverse correlation was
observed between the expression of E2F1 and MYCN mRNA
and protein in OBP-301- and OBP-702-infected NB tumor
cells (Figure 3C; Figure S5). These results suggest that E2F1
plays a role in virus-mediated downregulation of MYCN
expression.
E2F1 Is Involved in Oncolytic Adenovirus-Induced MYCN
Suppression
To explore the relationship between MYCN and E2F1, we used the
E2F1-expressing non-replicating adenovirus Ad-E2F1. Ectopic
expression of E2F1 induced by Ad-E2F1 downregulated the
expression of MYCN mRNA and protein in IMR-32 and CHP-
134 cells (Figures 4A–4C). Pretreatment with E2F1 small inter-
fering RNA (siRNA) attenuated the MYCN downregulation in
Ad-E2F1-infected NB cells via E2F1 suppression (Figure 4D). In16 Molecular Therapy: Oncolytics Vol. 18 September 2020contrast, no suppression of MYCN protein expression was
observed in NB cells infected with the E1A deletion control adeno-
virus dl312 (Figure S6). These results suggest that virus-mediated
E2F1 activation downregulates MYCN expression in MYCN-
amplified NB cells.
OBP-702-Mediated p53 Activation Is Attenuated during the Late
Phase of Virus Infection
We previously demonstrated that OBP-702 induces a more profound
antitumor effect than OBP-301 in various types of tumor cells via p53
activation.11,14 Therefore, we hypothesized that the OBP-702-
induced antitumor effect is associated with p53 activation in
MYCN-amplified NB cells. We prepared protein lysates from IMR-
32 and CHP-134 cells at 0, 24, 48, and 72 h after infection with
OBP-301 or OBP-702. Adenoviral E1A expression was increased at
24–48 h, and expression of the downstream mediator E2F1 was
increased at 48–72 h after infection with OBP-301 or OBP-702 (Fig-
ure 5). In OBP-301-infected NB cells, MYCN expression was
decreased at 48 h, consistent with E2F1 upregulation. In contrast,
in OBP-702-infected NB cells, MYCN expression was decreased at
24 h, consistent with p53 upregulation, and MYCN suppression
was enhanced at 48–72 h, consistent with E2F1 upregulation, even
though p53 expression was decreased. These results suggest that
E2F1 rather than p53 is mainly involved in OBP-702-mediated
MYCN downregulation.
Figure 3. OBP-301 and OBP-702 Induce MYCN Downregulation in Association with E2F1 Upregulation
(A) Expression of MYCNmRNA in IMR-32 and CHP-134 cells infected with OBP-301 or OBP-702 at the indicated MOI for 72 h. The value of MYCNmRNA in mock-infected
cells was set at 1, and the relative level of MYCNmRNA in infected cells was plotted as fold induction. Data are expressed asmean ± SD (n = 3). *p < 0.05 (versus anMOI of 0).
(B) Expression of MYCN and E2F1 protein in IMR-32 and CHP-134 cells infected with OBP-301 or OBP-702 at the indicated MOI for 72 h. b-Actin was assayed as a loading
control. The expression level of MYCN protein was calculated relative to that of mock-infected cells, which was set at 1.0. The expression of E2F1 protein was calculated
relative to that of the most E2F1-active cells, which was set at 1.0. (C) Correlation between the expression levels of E2F1 and MYCN protein in IMR-32 and CHP-134 cells
infected with OBP-301 or OBP-702.
www.moleculartherapy.orgIn Vivo Antitumor Effect of hTERT-Driven Oncolytic
Adenoviruses in a Subcutaneous CHP-134 Xenograft Tumor
Model
Finally, to assess the in vivo antitumor effect of the hTERT-driven on-
colytic adenoviruses, we used a subcutaneous CHP-134 xenograft tu-
mor model. We performed two in vivo experiments using different
protocols of virus treatment. OBP-301, OBP-702, or PBS was injected
intratumorally one time a week or three times a week for three cycles.
Although three administrations of viruses were not enough to sup-
press tumor growth (Figure S7), nine administrations of OBP-301
or OBP-702 significantly suppressed tumor growth compared to
PBS in the CHP-134 tumor xenograft model (Figures 6A and 6B).
However, there was no statistically significant difference in tumor vol-
ume between OBP-301 and OBP-702 treatment. Immunohistochem-
ical analyses revealed decreased levels of MYCN expression in both
OBP-301- and OBP-702-treated tumors (Figure 6C). Furthermore,
compared to control tumors, virus-treated tumors exhibited a signif-
icant decrease in the percentage of Ki67-positive proliferating cells(Figure 6D). In contrast, the p53 expression was not detected in
CHP-134 tumors (Figure S8). These results suggest that frequent ad-
ministrations of OBP-301 and OBP-702 have high therapeutic poten-
tial for use in eliminating MYCN-amplified NB tumors.
DISCUSSION
Recent comprehensive genomic analyses demonstrated that high-risk
NB tumors are characterized by MYCN amplification and/or hTERT
rearrangement, which contributes to high hTERT expression and
subsequent unfavorable prognosis. In this study, we confirmed that
the hTERT-driven oncolytic adenoviruses OBP-301 and OBP-702
have therapeutic antitumor potential against MYCN-amplified NB
cells exhibiting high hTERT expression via the induction of auto-
phagy. The virus-mediated antitumor effect is associated with
MYCN downregulation, involving virus-induced E2F1 activation.
Thus, hTERT-targeted oncolytic virotherapy appears to be a prom-
ising antitumor strategy for eliminating MYCN-amplified NB tumor
cells via MYCN suppression.Molecular Therapy: Oncolytics Vol. 18 September 2020 17
Figure 4. E2F1 Activation Induces MYCN
Downregulation
(A) Expression of E2F1 protein in IMR-32 and CHP-134
cells infected with Ad-E2F1 at the indicated MOI for 72 h.
(B) Expression of MYCN mRNA in IMR-32 and CHP-134
cells infected with Ad-E2F1 at the indicated MOI for 72 h.
The value of MYCN mRNA expression in mock-infected
cells was set at 1, and the relative level of MYCNmRNA in
infected cells was plotted as fold induction. Data are ex-
pressed as mean ± SD (n = 3; *p < 0.05 [versus an MOI of
0]). (C) Expression of MYCN protein in IMR-32 and CHP-
134 cells infected with Ad-E2F1 at the indicated MOI for
72 h. (D) Expression of MYCN and E2F1 protein in IMR-32
and CHP-134 cells pretreated with control siRNA or E2F1
siRNA (100 nM) before mock infection or Ad-E2F1
infection (100 MOI). b-Actin was assayed as a loading
control.
Molecular Therapy: OncolyticsAll MYCN-amplified NB cells exhibited high hTERT expression.
Although NB-1 cells showed the highest expression of hTERT
mRNA, they had the lowest expression of MYCN protein. Recent
reports have shown that only NB-1 cells have hTERT promoter
mutation among four MYCN-amplified NB cells.19,20 In addition,
non-MYCN-amplified SK-N-SH cells have an hTERT promoter
mutation.20 SK-N-SH cells were sensitive to OBP-301 and OBP-
702, similar to MYCN-amplified NB-1 cells. As hTERT promoter
mutation is frequently observed in specific types of cancers with
high hTERT expression,21 hTERT-driven oncolytic adenoviruses
may be effective to human cancer cells with hTERT promoter
mutation.
Autophagy is a catabolic process that induces the lysosomal degra-
dation of intracellular organelles to generate nutrients. In tumor
biology, autophagy plays dual roles associated with both cytopro-
tective and cytotoxic effects. Belounis et al.22 reported that chemo-
therapy induces autophagy associated with survival in NB cells,
contributing to apoptosis suppression and chemoresistance. In
contrast, oncolytic adenoviruses have been shown to induce auto-
phagy associated with cell death in tumor cells via the induction of
excessive autophagy.23 In our study, OBP-301 and OBP-702 ex-
hibited an antitumor effect in association with the autophagy-
related death of MYCN-amplified NB cells. We previously re-
ported that OBP-301 induces autophagy-related death of human
lung cancer cells.24 Moreover, the mTOR inhibitor rapamycin
improved the antitumor effect of the hTERT-driven oncolytic
adenovirus OBP-405 with modified fibers against brain tumor cells
via enhanced autophagy.25 Combining hTERT-driven oncolytic
adenoviruses and an autophagy-inducing mTOR inhibitor could
be a more effective strategy for inducing the death of MYCN-
amplified NB cells.18 Molecular Therapy: Oncolytics Vol. 18 September 2020MYCN plays a critical role in maintaining the
malignant potential of NB tumors via the acti-
vation of survival, proliferation, metastasis,
and angiogenesis processes.4 Therefore,MYCN inhibition is an attractive therapeutic strategy for eliminating
MYCN-amplified NB cells. In this study, the hTERT-driven oncolytic
adenoviruses OBP-301 and OBP-702 efficiently suppressed MYCN
expression to produce an antitumor effect. Consistent with our
data, Li et al.26 demonstrated that oncolytic adenoviruses with a
short-hairpin RNA targetingMYCN exert an antitumor effect against
MYCN-amplified NB cells by reducing MYCN expression. Regarding
the underlying mechanism of virus-mediated MYCN suppression, we
demonstrated that E2F1 upregulation downregulates MYCN expres-
sion at both themRNA and protein levels in OBP-301- and OBP-702-
infected NB cells. Some reports have described a possible relationship
between MYCN and E2F1. Verena et al.27 demonstrated that E2F
family proteins repress MYCN expression at the transcriptional level
in NB cells by binding to the promoter region of theMYCN gene. In
contrast, Strieder and Lutz28 reported that the E2F1-induced micro-
RNA-202 suppresses MYCN expression in NB cells at the posttran-
scriptional level. Although the underlying mechanism of E2F1-medi-
ated MYCN downregulation during oncolytic virotherapy remains
unclear, our data suggest that hTERT-driven oncolytic adenoviruses
are promising antitumor reagents for eliminating MYCN-amplified
NB cells via E2F1-mediated MYCN downregulation.
OBP-702-mediated p53 activation downregulated MYCN expression
during the early phase (24 h after infection). However, OBP-702-
mediated p53 activation was attenuated during the late phase (48
and 72 h after infection). Moreover, the antitumor effect of OBP-
301 and OBP-702 was similar in our subcutaneous xenograft tumor
model, suggesting that MYCN-amplified NB cells are relatively insen-
sitive to p53 activation. Although p53 mutations are rare in NB tu-
mors, occurring in less than 2% of cases at diagnosis,29,30 p53 is often
functionally inactivated in MYCN-amplified NB tumors via both
direct and indirect mechanisms. With regard to the direct mechanism
Figure 5. OBP-702-Mediated p53 Activation Is Not Involved in MYCN Downregulation
IMR-32 andCHP-134 cells were infected with OBP-301 or OBP-702 at anMOI of 100, and cells were harvested at the indicated time points. The levels of E1A, p53, PARP, C-
PARP, LC3-I, LC3-II, E2F1, and MYCN protein in cell lysates were analyzed by western blotting. b-Actin was assayed as a loading control.
www.moleculartherapy.orgof inactivation, the binding of MYCN to the C-terminal region of p53
results in the inactivation of target genes downstream of p53.31 With
regard to the indirect mechanism in contrast, MYCN-mediated
MDM2 activation suppresses p53 expression in MYCN-amplified
NB cells via the ubiquitin-proteasome pathway.32,33 Thus, MYCN-
amplified NB cells may be less sensitive to p53-mediated MYCN sup-
pression compared to E2F1-mediated MYCN suppression.
Personalized medicine approaches based on genetic alterations have
recently emerged for the treatment of various high-risk pediatric can-
cers, including NB.34 Although MYCN activation is the most prom-
ising therapeutic target in the treatment of high-risk NB patients, ef-
forts to develop drugs that directly target MYCN have not been
successful.6 Therefore, the development of inhibitors that indirectly
target MYCN-related signaling pathways has been challenging.35 In
this study, we confirmed the in vitro and in vivo therapeutic potential
of telomerase-targeted oncolytic adenoviruses against MYCN-ampli-
fied NB cells. MYCN suppression is a crucial factor in the underlying
mechanism of the virus-mediated antitumor effect. Recent compre-
hensive genomic analyses demonstrated that hTERT is commonly
activated in high-risk NB patients exhibiting MYCN amplification36
or hTERT rearrangement.7,8 Therefore, our novel hTERT-driven on-
colytic virotherapy could be a particularly useful antitumor strategy
for eliminating high-risk NB cells exhibiting MYCN amplification
or hTERT rearrangement.
NB tumors most frequently originate from the adrenal gland and
retroperitoneal lesions within the body.We can target primary NB tu-
mors by ultrasound imaging or intraoperative injection of oncolytic
adenoviruses. To inject these viruses to residual tumors that are un-
resectable by surgery may be an effective option for the local control
of primary NB tumors. However, MYCN-amplified NB cells
frequently develop metastatic tumors at the distant organs, whichare inaccessible for intratumor injections of oncolytic adenoviruses.
Therefore, we need to develop a therapeutic strategy to target inacces-
sible metastatic NB tumors. Recent evidence has suggested that onco-
lytic virotherapy induces an antitumor immune response via induc-
tion of immunogenic cell death.37–39 Oncolytic adenoviruses have
been shown to induce immunogenic cell death via the release of dam-
age-associated molecular patterns.40 We recently revealed that intra-
tumoral injection of hTERT-driven oncolytic adenoviruses at the pri-
mary site enhances the therapeutic potential of immune checkpoint
inhibitors in metastatic colorectal tumors at the liver.41 Therefore,
additional in vivo experiments would be warranted to investigate
the therapeutic potential of combination therapy with hTERT-driven
oncolytic adenoviruses and immunotherapy against metastatic NB
tumors.
In conclusion, we demonstrated that use of the telomerase-targeted
oncolytic adenoviruses OBP-301 and OBP-702 represents a prom-
ising therapeutic approach for the treatment of MYCN-amplified
NB tumors via MYCN suppression. To investigate the safety and
feasibility of telomerase-targeted oncolytic virotherapy, further clin-
ical study is warranted in high-risk NB patients exhibiting MYCN
and hTERT overexpression.
MATERIALS AND METHODS
Cell Lines
The human NB cell lines IMR-32 and NB-1 were obtained from the
Japanese Cancer Research Resources Bank (Osaka, Japan). The hu-
man NB cell lines CHP-134 and LA-N-5 were purchased from the
RIKEN BioResource Center (Tsukuba, Japan). These four NB cell
lines were previously reported as MYCN-amplified NB cells.42,43
The human NB cell line SK-N-SH was obtained from the RIKEN Bio-
Resource Center. SK-N-SH cells were used as non-MYCN-amplified
NB cells.18 All NB cell lines have a wild-type p53 gene, as shown by aMolecular Therapy: Oncolytics Vol. 18 September 2020 19
Figure 6. OBP-301 and OBP-702 Inhibit Tumor Growth in a Subcutaneous CHP-134 Xenograft Tumor Model
CHP-134 cells (1  107 cells) were inoculated into the flank of 6-week-old female BALB/c nu/nu mice. OBP-301 (108 PFU), OBP-702 (108 PFU), or PBS (mock) was in-
tratumorally injected three times a week for three cycles. (A) Tumor growth is expressed as mean tumor volume ± SD (n = 10 or 11 in each group; *p < 0.05). (B) Macroscopic
appearance of all isolated tumors in each group. (C) Histologic analysis of CHP-134 tumors. Tumor tissues were obtained at 7 weeks after tumor inoculation. Paraffin-
embedded sections of CHP-134 tumors were stained with hematoxylin and eosin (H&E) solution, anti-MYCN antibody, or anti-Ki67 antibody. Left, middle, and right images
showH&E, MYCN, and Ki67 staining, respectively. Left-side images in each figure are lowmagnification, and right-sides images are highmagnification of the area outlined by
a black square. Left scale bars, 200 mm. Right scale bars, 100 mm. (D) Percentage of Ki67-positive cells in tumor tissue was calculated using ImageJ software. Data are
expressed as mean ± SD (n = 5 in each group; *p < 0.05).
Molecular Therapy: Oncolyticsrecent report.44 The human non-small-cell lung cancer cell line
H1299 was obtained from the American Type Culture Collection
(Manassas, VA, USA). The human normal fibroblast cell line WI-
38 was purchased from the Health Science Research Resources
Bank (Osaka, Japan). Cells were cultured for no longer than 5 months
following resuscitation. Authentication was not performed by the au-
thors. We confirmed that there was no mycoplasma contamination in
all cell lines using PCR-based Myco Finder analysis (Nissui Pharma-
ceutical) according to the manufacturer’s protocol. IMR-32 cells were
maintained in Eagle’s minimal essential medium with non-essential
amino acids and 10% fetal bovine serum (FBS). CHP-134, LA-N-5,
and H1299 cells were maintained in RPMI 1640 supplemented with
10% FBS. NB-1 cells were cultured in RPMI 1640 (45%) with Eagle’s
minimal essential medium (45%) and 10% FBS. SK-N-SH cells were
maintained in minimal essential medium alpha with 10% FBS. WI-38
cells were maintained in Eagle’s minimal essential medium with 10%
FBS. All media were supplemented with 100 U/mL penicillin and
100 mg/mL streptomycin. Cells were routinely maintained at 37C
in a humidified atmosphere with 5% CO2.20 Molecular Therapy: Oncolytics Vol. 18 September 2020Recombinant Adenoviruses
The telomerase-specific replication-competent adenovirus OBP-301
(Telomelysin), in which the promoter element of the hTERT gene de-
rives expression of the E1A and E1B genes, was previously con-
structed and characterized.10,12 OBP-702 was constructed by modi-
fying OBP-301 to express the exogenous p53 gene by inserting a
human wild-type p53 gene expression cassette driven by the Egr-1
promoter into the E3 region of OBP-301.11 Replication-deficient
adenovirus vectors expressing E2F1 (Ad-E2F1) were used to induce
E2F1 expression in the infected cells, as previously reported.45 An
E1A-deletion adenovirus vector (dl312) was used as a control vector.
Recombinant adenoviruses were purified using cesium chloride step
gradients, and virus titers were determined using a plaque-forming
assay with 293 cells. Viruses were stored at 80C.
Flow Cytometry Analysis
Cells (5  104) were labeled with mouse anti-CAR monoclonal anti-
body (mAb) (RmcB; Upstate Biotechnology, Lake Placid, NY, USA)
for 30 min at 4C and then incubated with secondary fluorescein
www.moleculartherapy.orgisothiocyanate (FITC)-conjugated rabbit anti-mouse immunoglob-
ulin G (IgG) (Zymed Laboratories, South San Francisco, CA, USA).
Labeled cells were analyzed using flow cytometry (fluorescence-acti-
vated cell sorting [FACS] array; Becton Dickinson, San Jose, CA,
USA).
Cell Viability Assay
Cells were seeded in 96-well plates at a density of 5 103 cells/well or
2 104 cells/well 24 h before virus infection. Cells were infected with
OBP-301 or OBP-702 at a multiplicity of infection (MOI) of 0, 1, 10,
50, or 100 plaque-forming units (PFU)/cell. Cell viability was deter-
mined on day 3 after virus infection using a Cell Proliferation Kit II
(Roche, Indianapolis, IN, USA) according to the manufacturer’s
protocol.
Western Blot Analysis
IMR-32 and CHP-134 cells were seeded in a 100-mm dish at a density
of 1 106 and 2 106 cells/dish, respectively, 24 h before virus infec-
tion. Cells were infected with OBP-301, OBP-702, or Ad-E2F1 at the
indicated MOI for 72 h. Whole-cell lysates were prepared in lysis
buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, and 1% Triton
X-100) containing a protease inhibitor cocktail (Complete Mini;
Roche). Proteins were electrophoresed on 6%–15% SDS polyacryl-
amide gels and transferred onto polyvinylidene fluoride membranes
(Hybond-P; GE Healthcare, Buckinghamshire, UK). Blots were
blocked with Blocking One (Nacalai Tesque, Kyoto, Japan) at room
temperature for 30 min. The primary antibodies used were as follows:
rabbit anti-MYCN mAb (Cell Signaling Technology, Danvers, MA,
USA), mouse anti-Ad5 E1A mAb (BD Pharmingen, Franklin Lakes,
NJ, USA), mouse anti-p53 mAb (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), rabbit anti-PARP polyclonal antibody (pAb) (Up-
state Biotechnology, Temecula, CA, USA), rabbit anti-microtubule-
associated protein 1 light chain 3 (LC3) pAb (Medical & Biological
Laboratories [MBL], Nagoya, Japan), rabbit anti-E2F1 mAb (Cell
Signaling Technology), and mouse anti-b-actin mAb (Sigma-Al-
drich). The secondary antibodies used were horseradish peroxidase-
conjugated antibodies against rabbit IgG (GE Healthcare) or mouse
IgG (GE Healthcare). Immunoreactive bands on the blots were visu-
alized using enhanced chemiluminescence substrate (ECL Plus; GE
Healthcare).
Quantitative Real-Time RT-PCR Analysis
To evaluate the expression of hTERTmRNA, cells were seeded in six-
well plates at a density of 2 105 cells/well, and after 72 h, total RNA
was extracted from the cells using a miRNeasy mini kit (QIAGEN,
Valencia, CA, USA). To evaluate the expression ofMYCN in virus-in-
fected tumor cells, IMR-32 (2  105 cells/well) and CHP-134 cells
(4 105 cells/well) were seeded in six-well plates 24 h before infection
with OBP-301, OBP-702, or Ad-E2F1 at the indicated MOI. Total
RNA was extracted from cells on day 3 after infection using a miR-
Neasy mini kit (QIAGEN). cDNAwas synthesized from 10 ng of total
RNA using a TaqMan microRNA reverse transcription kit (Applied
Biosystems). The expression levels of hTERT,MYCN, and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) mRNA were deter-mined using quantitative real-time PCR with the Applied Biosystems
StepOnePlus real-time PCR system (Applied Biosystems). Relative
expression levels of hTERT mRNA were calculated using the 2DDCt
method after normalization with reference to the expression of
GAPDH mRNA.Infection with E2F1-Expressing Adenovirus and Treatment with
E2F1 siRNA
IMR-32 or CHP-134 cells were seeded at a density of 5  105 or 1 
106 cells/well in a 60-mm dish and transfected with E2F1 siRNA
(Applied Biosystems) or control siRNA (Applied Biosystems) at a
concentration of 100 nM. After 24 h, the cells were infected with
Ad-E2F1 at an MOI of 100 for 2 days. Whole-cell lysates were pre-
pared from the infected cells, and the expression levels of E2F1 and
MYCN protein were analyzed using western blotting.In Vivo Subcutaneous CHP-134 Xenograft Tumor Model
Animal experimental protocols were approved by the Ethics Review
Committee for Animal Experimentation of Okayama University
School of Medicine (no. OKU-2015364). CHP-134 xenograft tumors
were produced on the left flank of 6-week-old female BALB/c-nu/nu
mice (CLEA Japan, Tokyo, Japan) by subcutaneous injection of 1 
107 cells in 50 mL of PBS with 50 mL of Matrigel basement membrane
matrix (BD Biosciences, Bedford, MA, USA). When the tumors had
grown to a diameter of 4–6 mm, OBP-301 (1  108 PFU), OBP-
702 (1  108 PFU), or PBS was injected into the tumors one time a
week or three times a week for 3 cycles. Tumor size was monitored
by measuring tumor length and width using calipers (n = 10 or 11
in each group). CHP-134 tumor volume was calculated using the
following formula: (L  W2)  0.5, where L represents the length
and W represents the width of each tumor.Histopathologic Analysis
Tumors were fixed in 10% neutralized formalin and embedded in
paraffin blocks. Paraffin-embedded sections (4 mm) were prepared
for hematoxylin and eosin staining and immunohistochemical exam-
ination. Immunostaining with rabbit anti-MYCN mAb (Cell
Signaling Technology), rabbit anti-Ki67 mAb (Abcam, Cambridge,
MA, USA), or rabbit anti-p53 mAb (Cell Signaling Technology) ac-
cording to standard techniques was used to detect proliferating tumor
cells within tumor tissues. Photomicrographs of immunostained sec-
tions were obtained under light microscopy. The number of total cells
and Ki67-immunoreactive cells was determined from five randomly
selected fields in each tumor using ImageJ software.Statistical Analysis
Data are expressed as mean ± standard deviation (SD). Significant dif-
ferences were assessed using the Student’s t test. One-way ANOVA
followed by a Games-Howell multiple-group comparison test was
used to compare differences between groups in animal experiments.
Correlations between expression levels of E2F1 and MYCN protein
were analyzed using Spearman’s rank correlation coefficient. Statisti-
cal significance was defined as a p value of less than 0.05.Molecular Therapy: Oncolytics Vol. 18 September 2020 21
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